U.S. Supreme Court snubs Novartis appeal over arthritis drug Enbrel
The U.S. Supreme Court on Monday dashed Novartis AG’s (NOVN.S) hopes of launching a generic version of Amgen Inc’s (AMGN.O) multibillion-dollar rheumatoid arthritis Enbrel, declining to hear the company’s challenge to two patents on the drug.
The justices turned away Novartis subsidiary Sandoz Inc’s appeal of a lower court decision that upheld the validity of the patents.
Enbrel, a biologic also known as etanercept used to treat adults with moderate to severe active rheumatoid arthritis, is Amgen’s top-selling drug, accounting for nearly $5 billion of the company’s $24.2 billion in product sales for 2020. Enbrel was launched in 1998 by Immunex Corp, which Amgen acquired in 2002.
At issue in the case is a principle of U.S. patent law that prevents inventors from extending the life of their existing patents by obtaining more than one patent on the same invention, or an obvious variation of it.
The case involves the active ingredient in Enbrel. After Sandoz sought to market Erelzi, a generic version of Enbrel, Immunex sued in 2016 for patent infringement.
Sandoz accused Immunex of impermissibly extending the life of its monopoly on Enbrel through a 2004 deal that effectively took over rival Roche’s (ROG.S) patent applications on similar research and amended them to cover Enbrel. The successful applications now protect Enbrel from competition until 2029.
In 2020, the Washington-based U.S. Court of Appeals for the Federal Circuit, which specializes in patent cases, rejected Sandoz’s argument, saying that Roche did not transfer all of the rights to the new patents to Immunex.
Our Standards: The Thomson Reuters Trust Principles.